Martin Schechter | |
---|---|
Born | |
Alma mater | University of British Columbia Polytechnic Institute of New York York University McMaster University University of Toronto |
Known for | HIV/AIDS |
Awards | Order of British Columbia (1994) National Health Scientist Award in AIDS Science Council of British Columbia Gold Medal (2002) Fellow of the Royal Society of Canada (2004) Fellow of the Canadian Academy of Health Sciences (2004) Order of Canada (2022) |
Scientific career | |
Fields | Epidemiology |
Institutions | University of British Columbia |
Martin T. Schechter CM OBC (born December 16, 1951) is a Canadian epidemiologist recognized for contributions to research about HIV prevention and treatments, addiction research, and Indigenous health research. He is a professor and was the founding director of the School of Population and Public Health in the Faculty of Medicine at the University of British Columbia (UBC). Schechter received his Order of British Columbia in 1994 alongside BC's first Nobel Prize laureate Michael Smith and noted Indigenous artist Bill Reid. In 2022, Schechter was named as a Member of the Order of Canada. [1]
Schechter completed his Bachelor of Arts in mathematics at York University (1973), his Master of Arts in mathematics at UBC (1975), his Doctor of Philosophy in mathematics at the Polytechnic Institute of New York under the supervision of Wilhelm Magnus (1977), his MD in Medicine at McMaster University (1981) and his Master of Science in epidemiology at the University of Toronto (1983). [2]
Schechter combines interests in clinical epidemiology and health services research with HIV/AIDS and urban health research including opioid addiction research. He is also active in Indigenous health research. Schechter is the author of more than 400 peer-reviewed publications and 600 abstracts and scholarly presentations. [2]
When Schechter first began his work on AIDS research in 1983, there were no reported cases yet in British Columbia and embracing the necessity of an appropriate and humane response to HIV infection was not a popular activity at that time. [3] Airing public service announcements about condoms in movie theatres caused a public and private debate between Schechter and then-Premier of British Columbia Bill Vander Zalm. [4] Had HIV not been such an emerging health crisis, Schechter likely would have continued in the field of breast cancer. [4]
In 1989, he helped organize the Fifth International Conference on AIDS in Montreal as a member of its steering committee. In 1990, he was invited by the World Health Organization to participate on its 10-member Steering Committee on Epidemiology, Forecasting and Surveillance [3] that was monitoring the scale of the AIDS epidemic and advising on prevention programs in the early period of the epidemic.
Schechter co-founded the Canadian HIV Trials Network in 1990 with John Ruedy and Julio Montaner. Under Schechter's leadership as National Director from 1992 to 2014, the Network grew to become a nationwide collaboration of researchers, people living with HIV/AIDS and facilities to investigate treatments, preventions and vaccines for HIV/AIDS.
In 1992, he co-founded the British Columbia Centre for Excellence in HIV/AIDS and was its Director of Epidemiology and Public Health from 1992 - 2006. Schechter also co-founded the Canadian Association for HIV Research and served as its inaugural President in 1991.
In 1996, Schechter co-chaired the XI International AIDS Conference in Vancouver which attracted 15,000 delegates from around the world. It was at this global conference that the benefits of triple-therapy HAART were first fully revealed.
In 2004, he co-founded the Canadian Academy of Health Sciences, serving as its first President-Elect from 2004 to 2007 and second President from 2007 to 2009.
From 2006 to 2021, Schechter served as the inaugural Chief Scientific Officer of the Michael Smith Foundation for Health Research, and joined the inaugural board of the newly formed Michael Smith Health Research BC in 2021.
Schechter was the principal investigator and co-authored a study published in the New England Journal of Medicine about the controversial North American Opiate Medication Initiative (NAOMI). This 2005-2008 randomized controlled trial compared the use of diacetylmorphine (pharmaceutical heroin) and methadone in people with severe opioid dependence. In the NAOMI trial, researchers recruited 250 subjects in Vancouver and Montreal with at least five years of heroin addiction and who had twice previously not benefited from addiction treatment including methadone maintenance. The study found those receiving the effective element of heroin were 62 per cent more likely to remain in addiction treatment and 40 per cent less likely to take street drugs and commit crimes to support their habit than those given methadone. [5] Providing injections of medically prescribed heroin in a clinic setting was projected to save about $40,000 per person in lifetime societal costs compared to methadone. [6]
Schechter was also involved as a lead investigator in the follow-up to NAOMI, the Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) funded by Canadian Institutes of Health Research. [7] The SALOME trial established that the licensed analgesic drug, hydromorphone, was as effective as heroin in the treatment of severe opioid dependence, opening another avenue for treatment with injectable medications. In 2013, then Federal Health Minister Rona Ambrose controversially cancelled an approval from Health Canada regarding compassionate use of heroin for some research subjects after they completed the trial. Schechter questioned the value placed on research evidence by the federal government of the day. [8] The BMJ requested and published his commentary Drug users should be able to get heroin from the health system in April 2015. [9] [10]
Following a change in the Canadian federal government in 2015, substantive changes were made to Canadian policy regarding the use of diacetylmorphine and hydromorphone, particularly in response to the opioid overdose epidemic. In 2018, the Canadian government amended regulations to make medically prescribed heroin more accessible. Specifically, the new rules allow for administering diacetylmorphine outside of a hospital setting, and let nurse practitioners administer the drug. [11] In 2019, Canada became the first country in the world to approve the use of hydromorphone for severe opioid use disorder based on the results of the SALOME trial. [12]
This section of a biography of a living person does not include any references or sources .(April 2022) |
Along with Patricia Spittal and Kukpi Wayne Christian (Splatsin Secwepemc Nation), Schechter has served as principal investigator of the Cedar Project, funded by the Canadian Institutes of Health Research. The Cedar Project began in 2003 and involves 800 Indigenous participants between the ages of 14 and 30 who use non-injection and injection drugs. All aspects the study are led by the Cedar Project Partnership, an independent coalition of Indigenous Elders, leaders, and health/wellness experts. Cedar studies have highlighted the ongoing impacts of settler colonialism on Indigenous families and communities, including the foster care system, sexual abuse, extreme poverty, and racism. Cedar research has provided critical quantitative and qualitative evidence of these intergenerational colonial harms among young, street-involved Indigenous people who cope by using criminalized drugs. [13]
Along with Nadine Caron, Schechter helped to co-found the UBC Centre for Excellence in Indigenous Health in 2014, and they serve as its inaugural co-directors. The centre is a single coordinating point for Indigenous health initiatives within UBC and acts as a contact for communities and organizations external to UBC. The centre is dedicated to advancing Indigenous people's health through education, innovative thinking, research, and traditional practice. It works to improve wellness, health care and patient outcomes, and promote self-determination that includes increasing Indigenous leadership in all aspects of health and health care.
Heroin, also known as diacetylmorphine and diamorphine among other names, is a morphinan opioid substance synthesized from the dried latex of the opium poppy; it is mainly used as a recreational drug for its euphoric effects. Heroin is used medically in several countries to relieve pain, such as during childbirth or a heart attack, as well as in opioid replacement therapy. Medical-grade diamorphine is used as a pure hydrochloride salt. Various white and brown powders sold illegally around the world as heroin are routinely diluted with cutting agents. Black tar heroin is a variable admixture of morphine derivatives—predominantly 6-MAM (6-monoacetylmorphine), which is the result of crude acetylation during clandestine production of street heroin.
Methadone, sold under the brand names Dolophine and Methadose among others, is a synthetic opioid used medically to treat chronic pain and opioid use disorder. Prescribed for daily use, the medicine relieves cravings and opioid withdrawal symptoms. Withdrawal management using methadone can be accomplished in less than a month, or it may be done gradually over a longer period of time, or simply maintained for the rest of the patient's life. While a single dose has a rapid effect, maximum effect can take up to five days of use. After long-term use, in people with normal liver function, effects last 8 to 36 hours. Methadone is usually taken by mouth and rarely by injection into a muscle or vein.
Harm reduction, or harm minimization, refers to a range of intentional practices and public health policies designed to lessen the negative social and/or physical consequences associated with various human behaviors, both legal and illegal. Harm reduction is used to decrease negative consequences of recreational drug use and sexual activity without requiring abstinence, recognizing that those unable or unwilling to stop can still make positive change to protect themselves and others.
Hydromorphone, also known as dihydromorphinone, and sold under the brand name Dilaudid among others, is a morphinan opioid used to treat moderate to severe pain. Typically, long-term use is only recommended for pain due to cancer. It may be used by mouth or by injection into a vein, muscle, or under the skin. Effects generally begin within half an hour and last for up to five hours. A 2016 Cochrane review found little difference in benefit between hydromorphone and other opioids for cancer pain.
Opioid use disorder (OUD) is a substance use disorder characterized by cravings for opioids, continued use despite physical and/or psychological deterioration, increased tolerance with use, and withdrawal symptoms after discontinuing opioids. Opioid withdrawal symptoms include nausea, muscle aches, diarrhea, trouble sleeping, agitation, and a low mood. Addiction and dependence are important components of opioid use disorder.
Buprenorphine, sold under the brand name Subutex among others, is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It can be used under the tongue (sublingual), in the cheek (buccal), by injection, as a skin patch (transdermal), or as an implant. For opioid use disorder, the patient must have moderate opioid withdrawal symptoms before buprenorphine can be administered under direct observation of a health-care provider.
A methadone clinic is a medical facility where medications for opioid use disorder (MOUD) are dispensed-—historically and most commonly methadone, although buprenorphine is also increasingly prescribed. Medically assisted drug therapy treatment is indicated in patients who are opioid-dependent or have a history of opioid dependence. Methadone is a schedule II (USA) opioid analgesic, that is also prescribed for pain management. It is a long-acting opioid that can delay the opioid withdrawal symptoms that patients experience from taking short-acting opioids, like heroin, and allow time for withdrawal management. In the United States, by law, patients must receive methadone under the supervision of a physician, and dispensed through the Opioid Treatment Program (OTP) certified by the Substance Abuse and Mental Health Services Administration and registered with the Drug Enforcement Administration.
Vincent Dole was an American doctor, who, along with his wife, Marie Nyswander, developed the use of methadone to treat heroin addiction. Dole and Nyswander, in establishing methadone maintenance treatment (MMT), improved treatment options in addiction medicine which for a century had been based on the conventional view that narcotic addiction was the result of an intractable moral defect. His work resulted in the partial re-legalization of opioid maintenance in the United States. For this contribution he was a recipient of the 1970 Canada Gairdner International Award, and the 1988 Albert Lasker Award for Clinical Medical Research.
Heroin-assisted treatment (HAT), or diamorphine-assisted treatment, refers to a type of Medication-Assisted Treatment (MAT) where semi-synthetic heroin is prescribed to opiate addicts who do not benefit from, or cannot tolerate, treatment with one of the established drugs used in opiate replacement therapy such as methadone or buprenorphine. For this group of patients, heroin-assisted treatment has proven superior in improving their social and health situation. Heroin-assisted treatment is fully a part of the national health system in Switzerland, Germany, the Netherlands, Canada, and Denmark. Additional trials are being carried out in the United Kingdom, Norway, and Belgium.
An opiate is an alkaloid substance derived from opium. It differs from the similar term opioid in that the latter is used to designate all substances, both natural and synthetic, that bind to opioid receptors in the brain. Opiates are alkaloid compounds naturally found in the opium poppy plant Papaver somniferum. The psychoactive compounds found in the opium plant include morphine, codeine, and thebaine. Opiates have long been used for a variety of medical conditions, with evidence of opiate trade and use for pain relief as early as the eighth century AD. Most opiates are considered drugs with moderate to high abuse potential and are listed on various "Substance-Control Schedules" under the Uniform Controlled Substances Act of the United States of America.
Marie Nyswander was an American psychiatrist and psychoanalyst known for developing and popularizing the use of methadone to treat heroin addiction.
Substance use disorder (SUD) is the persistent use of drugs despite substantial harm and adverse consequences to self and others. Related terms include substance use problems and problematic drug or alcohol use.
Julio S. G. Montaner is an Argentine-born Canadian physician, professor and researcher. He is the director of the British Columbia Centre for Excellence in HIV/AIDS, the chair in AIDS Research and head of the Division of AIDS in the Faculty of Medicine at the University of British Columbia and the past-president of the International AIDS Society. He is also the director of the John Ruedy Immunodeficiency Clinic, and the Physician Program Director for HIV/AIDS PHC. He is known for his work on HAART, a role in the discovery of triple therapy as an effective treatment for HIV in the late 1990s, and a role in advocating the "Treatment as Prevention" Strategy in the mid-2000s, led by Myron Cohen of the HPTN 052 trial.
Perry Kendall, is a Canadian Public health physician who was Provincial Health Officer (PHO) for the Canadian province of British Columbia's health ministry from 1999-2018 and was awarded the Order of British Columbia for contributions to Public health field and to harm reduction policy and practice.
Beny Jene Primm was a prominent American physician, HIV/AIDS researcher, lecturer, and advocate for public health policy reform.
Gerry Stimson is a British public health social scientist, emeritus professor at Imperial College London from 2004, and an honorary professor at the London School of Hygiene and Tropical Medicine from 2017. Stimson has over 220 scientific publications mainly on social and health aspects of illicit drug use, including HIV infection. He has sat on numerous editorial boards including AIDS, Addiction, and European Addiction Research, and with Tim Rhodes he was the co-editor-in-chief of the International Journal of Drug Policy from 2000 to 2016. He is one of the global leaders for research on and later advocacy for harm reduction.
Chronic addiction substitution treatment (CAST) is a policy adopted by Vancouver City Council in 2007 to reduce the harms of drug prohibition by providing substitutes to those with addictions.
Aslam Anis is a Bangladeshi-Canadian health economist whose primary areas of research involvement include health services research, measuring patient-reported outcomes, Canadian competition policy in the pharmaceutical industry, and the cost-effectiveness of treatments for HIV/AIDS, rheumatoid arthritis, and other conditions.
Opioid agonist therapy (OAT) is a treatment in which prescribed opioid agonists are given to patients who live with Opioid use disorder (OUD). In the case of methadone maintenance treatment (MMT), methadone is used to treat dependence on heroin or other opioids, and is administered on an ongoing basis.
Colleen Anne Dell is a Canadian public sociologist, animal-assisted intervention practitioner, and academic. She is a Professor and Centennial Enhancement Chair in One Health & Wellness in the Department of Sociology and Associate in the School of Public Health at the University of Saskatchewan. She is most known for her research on criminal justice, mental health, substance abuse, and Indigenous peoples’ health.